Published in J Cardiovasc Electrophysiol on May 01, 2003
Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. Circulation (2016) 1.49
Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J (2010) 1.10
Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally. Neth Heart J (2007) 1.08
Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm (2008) 1.07
Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J (2005) 0.99
Brugada syndrome. Orphanet J Rare Dis (2006) 0.84
The Brugada syndrome. Its relevance to paediatric practice. Z Kardiol (2004) 0.82
Inducible ventricular fibrillation in the Brugada syndrome: diagnostic and prognostic implications. J Cardiovasc Electrophysiol (2003) 0.77
Quinidine: an "endangered species" drug appropriate for management of electrical storm in brugada syndrome. Indian Pacing Electrophysiol J (2013) 0.77
Risk stratification in electrical cardiomyopathies. Herz (2009) 0.76
Flecainide challenge test: Predictors of unmasking of type 1 Brugada ECG pattern among those with non-type 1 Brugada ECG pattern. Indian Pacing Electrophysiol J (2016) 0.75
To the editor. J Cardiovasc Electrophysiol (2003) 0.75
Brugada Syndrome:Risk Stratification And Management. J Atr Fibrillation (2016) 0.75
Risk stratification in young patients with channelopathies. Indian Pacing Electrophysiol J (2010) 0.75
Risk factors for cardiac events in patients with Brugada syndrome: A PRISMA-compliant meta-analysis and systematic review. Medicine (Baltimore) (2016) 0.75
Outcomes of Brugada Syndrome Patients with Coronary Artery Vasospasm. Intern Med (2017) 0.75
[Brugada syndrome]. Herzschrittmacherther Elektrophysiol (2013) 0.75
Brugada Syndrome:Risk Stratification And Management. J Atr Fibrillation (2016) 0.75
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med (2015) 4.17
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation (2011) 3.00
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol (2008) 2.68
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol (2005) 2.39
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace (2008) 2.32
De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res (2005) 2.27
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Effect of opening a new catheterization laboratory on 30-day and 2-year survival rates in myocardial infarction patients. Rev Esp Cardiol (2011) 2.14
Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2006) 2.11
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Electrocardiographic recognition of the epicardial origin of ventricular tachycardias. Circulation (2004) 2.05
The European cardiac resynchronization therapy survey. Eur Heart J (2009) 2.04
Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? Eur J Heart Fail (2012) 2.04
Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. Eur J Heart Fail (2013) 2.03
Brugada syndrome. Rev Esp Cardiol (2009) 2.03
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation (2004) 2.00
Nonsurgical transthoracic epicardial radiofrequency ablation: an alternative in incessant ventricular tachycardia. J Am Coll Cardiol (2003) 1.97
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace (2013) 1.97
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 1.94
Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation (2003) 1.92
Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm (2009) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J (2007) 1.86
Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J (2013) 1.83
Cryptic 5' splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol (2004) 1.81
Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation (2008) 1.81
HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm (2008) 1.79
Assessment of mitral valve anatomy and geometry with multislice computed tomography. JACC Cardiovasc Imaging (2009) 1.75
Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J (2007) 1.75
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Assessment of left ventricular dyssynchrony by real-time three-dimensional echocardiography. Rev Esp Cardiol (2008) 1.74
Electrophysiologic testing predicts events in Brugada syndrome patients. Heart Rhythm (2011) 1.70
Tailored echocardiographic interventricular delay programming further optimizes left ventricular performance after cardiac resynchronization therapy. Heart Rhythm (2005) 1.70
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace (2008) 1.68
Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol (2008) 1.67
Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation. J Cardiovasc Electrophysiol (2013) 1.67
Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J (2011) 1.64
Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J (2009) 1.63
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63
Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest (2003) 1.62
State of the art in forensic investigation of sudden cardiac death. Am J Forensic Med Pathol (2011) 1.61
Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace (2010) 1.61
Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace (2008) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace (2010) 1.55
Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol (2011) 1.55
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm (2012) 1.54
Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol (2003) 1.54
Current practice of ventricular tachycardia ablation in patients with implantable cardioverter-defibrillators. Europace (2012) 1.52
Mechanism of decrease in mitral regurgitation after cardiac resynchronization therapy: optimization of the force-balance relationship. Circ Cardiovasc Imaging (2009) 1.52
Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol (2007) 1.52
Performance and survival of transvenous defibrillation leads: need for a European data registry. Europace (2008) 1.51
Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res (2011) 1.51
Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace (2010) 1.50
The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics (2002) 1.50
[Integration between cardiology and primary care: impact on clinical practice]. Rev Esp Cardiol (2011) 1.49